Kane Biotech Stock Shares Outstanding
KNBIF Stock | USD 0.08 0.0003 0.39% |
Kane Biotech fundamentals help investors to digest information that contributes to Kane Biotech's financial success or failures. It also enables traders to predict the movement of Kane OTC Stock. The fundamental analysis module provides a way to measure Kane Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kane Biotech otc stock.
Kane |
Kane Biotech OTC Stock Shares Outstanding Analysis
Kane Biotech's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Kane Biotech Shares Outstanding | 124.83 M |
Most of Kane Biotech's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kane Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Kane Biotech has 124.83 M of shares currently outstending. This is 30.86% lower than that of the Healthcare sector and 16.82% higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is 78.17% higher than that of the company.
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
All Next | Launch Module |
Kane Fundamentals
Return On Equity | -5.97 | |||
Return On Asset | -0.39 | |||
Profit Margin | (1.80) % | |||
Operating Margin | (1.72) % | |||
Current Valuation | 12.47 M | |||
Shares Outstanding | 124.83 M | |||
Shares Owned By Insiders | 26.82 % | |||
Price To Earning | 4.68 X | |||
Price To Book | 102.61 X | |||
Price To Sales | 3.45 X | |||
Revenue | 1.61 M | |||
Gross Profit | 568.44 K | |||
EBITDA | (4.25 M) | |||
Net Income | (4.6 M) | |||
Cash And Equivalents | 2.53 M | |||
Cash Per Share | 0.02 X | |||
Total Debt | 1.12 M | |||
Debt To Equity | 7.12 % | |||
Current Ratio | 0.67 X | |||
Book Value Per Share | (0.05) X | |||
Cash Flow From Operations | (2.29 M) | |||
Earnings Per Share | (0.03) X | |||
Number Of Employees | 18 | |||
Beta | 0.19 | |||
Market Capitalization | 10.45 M | |||
Total Asset | 6.13 M | |||
Z Score | 5.4 | |||
Net Asset | 6.13 M |
About Kane Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kane Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kane Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kane Biotech based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Kane OTC Stock
Kane Biotech financial ratios help investors to determine whether Kane OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.